Pfizer Sued Over Carcinogen Found in Smoking Cessation Drug

Pfizer Inc. should have conducted better testing to look for carcinogenic nitrosamine impurities in Chantix, a consumer says on behalf of a proposed class in the wake of the drugmaker’s recall of nine lots of the smoking cessation drug.

The “presence of nitrosamines in prescription medications has been the subject of FDA scrutiny for over three years, as well as international regulators such as the European Medicines Agency,” Roslyn Harris says in a complaint filed Thursday in the U.S. District Court for the Southern District of New York.

Pfizer said in June that it was pausing worldwide distribution of Chantix ...